May 01, 2026
Life Science Magazines About Us Contact Us
Life Science Newswire Service™ (LS)
Submit a Press Release
  • Analytical chemistry
  • Business
  • Biomanufacturing & bioprocessing
  • Biotechnology
  • Diagnostics
  • Drug development
  • More News
    • Environmental Science
    • Food & beverage
    • Forensic science
    • Healthcare
    • Hospitals
    • Lab tools
    • Materials science
    • Microbiology
    • Nanotechnology
    • Pharma & Biopharma
    • Pharmacy
    • Veterinary
    • Water Management
  • Press Releases
Reading: Federal Circuit Vacates $300 Million Verdict Against Apple, Orders Third Trial in LTE Patent Dispute
Share
Font ResizerAa
Life Science Newswire Service™ (LS)Life Science Newswire Service™ (LS)
Search
  • Business
  • Press Releases
  • Life Science Magazines
  • Life Sciences
    • Analytical chemistry
    • Biomanufacturing & bioprocessing
    • Biotechnology
    • Diagnostics
    • Drug development
    • Environmental Science
    • Food & beverage
    • Forensic science
    • Healthcare
    • Hospitals
    • Lab tools
    • Materials science
    • Microbiology
    • Nanotechnology
    • Pharma & Biopharma
    • Pharmacy
    • Veterinary
    • Water Management
  • About Us
  • Contact Us
  • Submit a Press Release
LS Newswire Service™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC
Life Science Newswire Service™ (LS) > Blog > Life Sciences > Biotechnology > Federal Circuit Vacates $300 Million Verdict Against Apple, Orders Third Trial in LTE Patent Dispute
Biotechnology

Federal Circuit Vacates $300 Million Verdict Against Apple, Orders Third Trial in LTE Patent Dispute

By Newsroom
Last updated: July 11, 2025
1 Min Read
Share


In a pivotal ruling for patent damages and standard-essential patent (SEP) litigation, the Federal Circuit vacated a $300 million award against Apple in a long-standing dispute with Optis Cellular Technology, LLC. See Optis Cellular Tech., LLC v. Apple Inc. (“Op.”). The Federal Circuit sided with Apple on multiple fronts—vacating the damages and infringement findings, reversing § 101 findings on the claims of one of Optis’s patents, and reversing a finding that another patent did not invoke 35 USC § 112 ¶6 (The patent at issue was issued pre-AIA so §112(f) is referred to as 112 ¶ 6 as in the original statute language). The…



Source link

Share This Article
Facebook Email Copy Link Print

HOT NEWS

Ontario passes first wave of streamlining for the Clean Water Act

Environmental Science
November 23, 2025

Radiopharmaceuticals Commercialization: What Determines…

From an investor perspective, radiopharmaceuticals present a distinct set of challenges, where clinical success must…

May 1, 2026

تُظهر الدراسة أن وجبة الإفطار الغنية بالجوز من الممكن أن تساعد في تعزيز قوة دماغك

California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…

April 5, 2025

Arab Newswire Provides Press Release Distribution in Arabic

Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…

April 5, 2025

YOU MAY ALSO LIKE

Back to District Court? PTAB Strategic Recalibration in Patent Litigation

For years, parallel proceedings at the Patent Trial and Appeal Board (PTAB) were the near-automatic response of a defendant in…

Biotechnology
February 22, 2026

FDA Proposes Risk-Based and Remote Inspection Strategies in New Report

On May 5, 2021, the U.S. Food and Drug Administration (FDA) issued a much-anticipated report, “Resiliency Roadmap for FDA Inspectional…

Biotechnology
April 5, 2025

FDA Year in Review: A Shifting Regulatory Landscape

The FDA actions that dominated 2019 demonstrated a shifting regulatory landscape for certain product types, such as e-cigarettes, foods and…

Biotechnology
April 12, 2025

Is the Patent Eligibility Act a Panacea for Claims to Diagnostics? |

On January 23, the Subcommittee on Intellectual Property held a hearing in which the members of the committee heard testimony…

Biotechnology
April 5, 2025
Life Science Newswire Service™ (LS)

Contact Us

  • Whatsapp: +1 832-716-2363
  • Skype: Groupwebmedia
  • Telegram: Groupwebmedia

Share Us

About Us

Life Science Newswire Services (LS)™ aggregates, publishes and distributed news about the Life Science industry. In association with EmailWire, LS provides press release distribution services in the Life Science sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us.

Categories

Analytical chemistry
Business
Biomanufacturing & bioprocessing
Biotechnology
Diagnostics
Drug development
Environmental Science
Food & beverage
Forensic science
Healthcare
Hospitals
Lab tools
Materials science
Microbiology
Nanotechnology
Pharma & Biopharma
Pharmacy
Veterinary
Water Management
Life Science Magazines
Press Releases

Recent News

Radiopharmaceuticals Commercialization: What Determines…
May 1, 2026
ثمانية أعوام من الإنجازات، ومستقبل لا نهاية له: BingX تُطلق جائزة بقيمة 10 ملايين دولار واحتفالات عالمية
May 1, 2026
8 Years On, Infinite Ahead: BingX Launches $10M Prize Pool and Global Celebrations
May 1, 2026
Radiopharmaceuticals: A Wall Street Perspective on Value and…
May 1, 2026

Life Science Magazines

Radiopharmaceuticals Commercialization: What Determines…
May 1, 2026
Radiopharmaceuticals: A Wall Street Perspective on Value and…
May 1, 2026
Managing Operational Complexity in Early-Phase Oncology…
May 1, 2026
Revolutionizing Drug Discovery From Undruggables To AI
May 1, 2026

LS Newswire Service™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?